Lowan Stewart
Medical Director, Axonklinikken, Oslo
Speaking at 1st KAP International Association Summit
Led the campaign behind Norway's national ketamine reimbursement decision
Founded Axonklinikken, Scandinavia's first dedicated ketamine clinic, in Oslo. Campaigned for the 2025 decision making Norway the first country to publicly fund generic ketamine for treatment-resistant depression. Also consults to the ketamine unit at DPS Nordre Østfold. Published multiple Tidsskriftet (Journal of the Norwegian Medical Association) articles on clinical ketamine and MDMA practice, most recently June 2026.
Public Company Affiliation
Solvonis Therapeutics plc (formerly Awakn Life Sciences Corp.) LSE: SVNS
Awakn Life Sciences Corp. — which announced acquiring Axonklinikken in 2021, naming Stewart Regional Director for the Nordics — was itself acquired by Solvonis Therapeutics plc, completing May 28, 2025; Awakn delisted from the CSE. Stewart's specific current role within Solvonis isn't independently confirmed beyond the original Awakn announcement.